Impact of various vaccine boosters on neutralization against omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine  

灭活疫苗或腺病毒载体疫苗初次免疫后不同疫苗加强针中和SARS-CoV-2 Omicron变异株的效果

作　　者：Qingrui Huang Jiawei Zeng Qingyun Lang Feng Gao Dejun Liu Siyu Tian Rui Shi Ling Luo Hao Wang Liping Hu Linrui Jiang Yawei Liu Kailiang Li Yunbo Wu Junjie Xu Wenxi Jiang Ning Guo Zhihai Chen Xiaohua Hao Ronghua Jin Jinghua Yan Yufa Sun 黄庆瑞;曾家伟;郎青云;高峰;刘德军;田丝雨;史瑞;罗玲;王浩;胡丽萍;蒋林芮;刘亚巍;李开亮;吴云波;许俊杰;蒋文溪;郭宁;陈志海;郝晓花;金荣华;严景华;孙玉发(CAS Key Laboratory of Pathogenic Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China;University of Chinese Academy of Sciences,Beijing 101408,China;College of Life Sciences,Anhui Agricultural University,Hefei 230036,China;Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China,Beijing 100017,China;Institute of Physical Science and Information,Anhui University,Hefei 230039,China;National Center for Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)

机构地区：[1]CAS Key Laboratory of Pathogenic Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China [2]University of Chinese Academy of Sciences,Beijing 101408,China [3]College of Life Sciences,Anhui Agricultural University,Hefei 230036,China [4]Health Service Department of the Guard Bureau of the General Office of the Central Committee of the Communist Party of China,Beijing 100017,China [5]Institute of Physical Science and Information,Anhui University,Hefei 230039,China [6]National Center for Infectious Diseases,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

出　　处：《Science Bulletin》2022年第13期1326-1330,M0003,共6页科学通报（英文版）

基　　金：supported by the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB29040201);the National Natural Science Foundation of China(NSFC)(81901680)。

摘　　要：SARS-CoV-2 Omicron变异株已在全球范围内广泛传播.包括中国在内的许多国家广泛接种了SARS-CoV-2灭活疫苗(IAV)、重组蛋白疫苗(PRV)和腺病毒载体疫苗(Ad V),以达到群体免疫效果.该研究系统评价了完成不同疫苗全程接种后以及接种不同疫苗加强针后的341份人血清对原始毒株和Omicron变异株的交叉中和活性.研究发现,所有类型疫苗诱导的针对Omicron变异株BA.1的中和抗体水平都明显低于原始毒株.初免疫IAV和Ad V后,分别接种Ad V和PRV的异源加强针可以最大程度地提高血清对Omicron中和活性.此外,该研究使用m RNA疫苗在小鼠模型中评估了初次免疫编码Spike蛋白的m RNA疫苗后,加强免疫编码原始毒株或者不同突变株RBD蛋白的m RNA疫苗对Omicron中和效果.结果发现,与原始毒株加强针相比,只有Omicron加强针疫苗显著地提升了Omicron的中和抗体水平.该研究对各种疫苗加强针的系统性评价可为接下来对抗Omicron变异株的免疫接种提供参考.

关 键 词：灭活疫苗 不同疫苗 免疫接种 初次免疫 PRV 系统性评价 群体免疫 中和活性 

分 类 号：R186[医药卫生—流行病学]